Therefore, it was hypothesized that AA patients for OPRM1, exhibiting a greater activation of the mu-receptor, would have cognitive deficits as described with the activation of the κOR, explaining their lower cognitive performance and the subsequent impact on their quality of life. The gene discussed is OPRK1; the disease is Cognitive impairment.